This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Linker, R. A. Articles by Kieseier, B. C. Search for Related Content Social Bookmarking                         What's this?

Review: Innovative monoclonal antibody therapies in multiple sclerosis

Department of Neurology St. Josef Hospital Ruhr-University Bochum D-44791 Bochum Germany, ralf.linker{at}rub.de

Bernd C. Kieseier

Department of Neurology Heinrich-Heine University Düsseldorf, Düsseldorf Germany

The recent years have witnessed great efforts in establishing new therapeutic options for multiple sclerosis (MS), especially for relapsing—remitting disease courses. In particular, the application of monoclonal antibodies provide innovative approaches allowing for blocking or depleting specific molecular targets, which are of interest in the pathogenesis of MS. While natalizumab received approval by the US Food and Drug Administration and the European Medicines Agency in 2006 as the first monoclonal antibody in MS therapy, rituximab, alemtuzumab, and daclizumab were successfully tested for relapsing-remitting MS in small cohorts in the meantime. Here, we review the data available from these recent phase II trials and at the same time critically discuss possible pitfalls which may be relevant for clinical practice. The results of these studies may not only broaden our therapeutic options in the near future, but also provide new insights into disease pathogenesis.

Key Words: immunotherapy • T-cell • B-cell • blood brain barrier • clinical trial

References

• Bar-Or, A., Calabresi, P.A., Arnlod, D., Markowitz, C., Shafer, S., Kasper, L.H. et al. (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63: 395-400.[CrossRef][Medline] [Order article via Infotrieve]
• Baron, J.L., Madri, J.A., Ruddle, N.H., Hashim, G. and Janeway Jr, C.A. (1993) Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 177: 57-68.[Abstract/Free Full Text]
• Bielekova, B., Catalfamo, M., Reichert-Scrivner, S., Packer, A., Cerna, M., Waldmann, T.A. et al. (2006) Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 103: 5941-5946.[Abstract/Free Full Text]
• Bielekova, B., Richert, N., Howard, T., Blevins, G., Markovic-Plese, S., McCartin, J. et al. (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 101: 8705-8708.[Abstract/Free Full Text]
• Chan, A., Lee, D.H., Linker, R., Mohr, A., Toyka, K.V. and Gold, R. (2007) Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease. J Neurol 254: 1604-1606.[CrossRef][Medline] [Order article via Infotrieve]
• Coles, A.J., Cox, A., Le, P.E., Jones, J., Trip, S.A., Deans, J. et al. (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253: 98-108.[CrossRef][Medline] [Order article via Infotrieve]
• Coles, A.J., Wing, M., Smith, S., Coraddu, F., Greer, S., Taylor, C. et al. (1999a) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354: 1691-1695.[CrossRef][Medline] [Order article via Infotrieve]
• Coles, A.J., Wing, M.G., Molyneux, P., Paolillo, A., Davie, C.M., Hale, G. et al. (1999b) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46: 296-304.[CrossRef][Medline] [Order article via Infotrieve]
• Coles, A., and the CAMMS223 Study Group ( 2007) Efficacy of Alemtuzumab in treatment-naive relapsing remitting multiple sclerosis: analysis after two yeares of study CAMMS223. Neurology Suppl 1: A100.
• Cree, B.A., Lamb, S., Morgan, K., Chen, A., Waubant, E. and Genain, C. (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64: 1270-1272.[Abstract/Free Full Text]
• Cross, A.H., Stark, J.L., Lauber, J., Ramsbottom, M.J. and Lyons, J.A. (2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 180: 63-70.[CrossRef][Medline] [Order article via Infotrieve]
• Dearden, C.E. (2002) Alemtuzumab in lymphoproliferate disorders. Rev Clin Exp Hematol 6: 435-448.[CrossRef][Medline] [Order article via Infotrieve]
• Flynn, J.M. and Byrd, J.C. (2000) Campath-1H monoclonal antibody therapy. Curr Opin Oncol 12: 574-581.[CrossRef][Medline] [Order article via Infotrieve]
• Gold, R., Jawad, A., Miller, D.H., Henderson, D.C., Fassas, A., Fierz, W. et al. (2007) Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol 187: 156-158.[CrossRef][Medline] [Order article via Infotrieve]
• Gross, J.A., Dillon, S.R., Mudri, S., Johnston, J., Littau, A., Roque, R. et al. (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 15: 289-302.[CrossRef][Medline] [Order article via Infotrieve]
• Hauser, S.L., Waubant, E., Arnold, D.L., Vollmer, T., Antel, J., Fox, R.J. et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676-688.[Abstract/Free Full Text]
• Huryn, D.M., Konradi, A.W., Ashwell, S., Freedman, S.B., Lombardo, L.J., Pleiss, M.A. et al. (2004) The identification and optimization of orally efficacious, small molecule VLA-4 antagonists. Curr Top Med Chem 4: 1473-1484.[CrossRef][Medline] [Order article via Infotrieve]
• Kappos, L., Bates, D., Hartung, H.P., Havrdova, E., Miller, D., Polman, C.H. et al. (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6: 431-441.[CrossRef][Medline] [Order article via Infotrieve]
• Kleinschmidt-DeMasters, B.K. and Tyler, K.L. (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353: 369-374.[Abstract/Free Full Text]
• Koch, M., Niemeyer, G., Patel, I., Light, S. and Nashan, B. (2002) Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation 73: 1640-1646.[CrossRef][Medline] [Order article via Infotrieve]
• Kohler, G. and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.[CrossRef][Medline] [Order article via Infotrieve]
• Krumbholz, M., Pellkofer, H., Gold, R., Hoffmann, L.A., Hohlfeld, R. and Kumpfel, T. (2007) Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol 64: 1331-1333.[Abstract/Free Full Text]
• Langer-Gould, A., Atlas, S.W., Green, A.J., Bollen, A.W. and Pelletier, D. (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353: 375-381.[Abstract/Free Full Text]
• Lassmann, H., Bruck, W. and Lucchinetti, C.F. (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17: 210-218.[CrossRef][Medline] [Order article via Infotrieve]
• Lee, Y.H., Ishida, Y., Rifa'i, M., Shi, Z., Isobe, K. and Suzuki, H. (2008) Essential role of CD8+CD122+ regulatory T cells in the recovery from experimental autoimmune encephalomyelitis. J Immunol 180: 825-832.[Abstract/Free Full Text]
• Lennon, V.A., Kryzer, T.J., Pittock, S.J., Verkman, A.S. and Hinson, S.R. (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202: 473-477.[Abstract/Free Full Text]
• Leussink, V.H., Lehmann, Hartung, H., Gold and Kieseier.,B. (2007) Type III systemic allergic reaction to natalizumab. Arch Neurol 64: 1331-1333.[Abstract/Free Full Text]
• Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A. et al. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195.[Abstract/Free Full Text]
• Miller, D.H., Khan, O.A., Sheremata, W.A., Blumhardt, L.D., Rice, G.P., Libonati, M.A. et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348: 15-23.[Abstract/Free Full Text]
• Montalban, X.D., Wynn, M., Kaufmann, M. and Wang, Fong A. (2007) Preliminary CHOICE results: a phase 2, randmomized, double-blind, placebo controllled multicentre study of subcutaneous daclizumab in patients with active, relapsing forms of multiple sclerosis on interferon beta. Mult Scler 13: S18.
• Moreau, T., Coles, A., Wing, M., Isaacs, J., Hale, G., Waldmann, H. et al. (1996) Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119(Pt 1): 225-237.
• Moreau, T., Thorpe, J., Miller, D., Moseley, I., Hale, G., Waldmann, H. et al. (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344: 298-301.[CrossRef][Medline] [Order article via Infotrieve]
• Mullen, J.T., Vartanian, T.K. and Atkins, M.B. (2008) Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 358: 647-648.[Free Full Text]
• Paolillo, A., Coles, A.J., Molyneux, P.D., Gawne-Cain, M., MacManus, D., Barker, G.J. et al. (1999) Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53: 751-757.[Abstract/Free Full Text]
• Petereit, H.F. and Rubbert, A. (2005) Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis. Arch Neurol 62: 1641-1642.[Free Full Text]
• Phillips, J.T., O'Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H. et al. (2006) Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology 67: 1717-1718.[Free Full Text]
• Polman, C.H., O'Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.[Abstract/Free Full Text]
• Ransohoff, R.M. (2007) Natalizumab for multiple sclerosis. N Engl J Med 356: 2622-2629.[Free Full Text]
• Rastetter, W., Molina, A. and White, C.A. (2004) Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 55: 477-503.[CrossRef][Medline] [Order article via Infotrieve]
• Rice, G.P., Hartung, H.P. and Calabresi, P.A. (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64: 1336-1342.[Abstract/Free Full Text]
• Riechmann, L., Clark, M., Waldmann, H. and Winter, G. (1988) Reshaping human antibodies for therapy. Nature 332: 323-327.[CrossRef][Medline] [Order article via Infotrieve]
• Rose, J.W., Burns, J.B., Bjorklund, J., Klein, J., Watt, H.E. and Carlson, N.G. (2007) Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69: 785-789.[Abstract/Free Full Text]
• Rose, J.W., Watt, H.E., White, A.T. and Carlson, N.G. (2004) Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 56: 864-867.[CrossRef][Medline] [Order article via Infotrieve]
• Rudick, R.A., Stuart, W.H., Calabresi, P.A., Confavreux, C., Galetta, S.L., Radue, E.W. et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911-923.[Abstract/Free Full Text]
• Sadatipour, B.T., Greer, J.M. and Pender, M.P. (1998) Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 44: 980-983.[CrossRef][Medline] [Order article via Infotrieve]
• Silber, E., Semra, Y.K., Gregson, N.A. and Sharief, M.K. (2002) Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 58: 1372-1381.[Abstract/Free Full Text]
• Stuve, O., Cepok, S., Elias, B., Saleh, A., Hartung, H.P., Hemmer, B. et al. (2005) Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 62: 1620-1623.[Abstract/Free Full Text]
• Stuve, O., Marra, C.M., Bar-Or, A., Niino, M., Cravens, P.D., Cepok, S. et al. (2006) Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63: 1383-1387.[Abstract/Free Full Text]
• Suntharalingam, G., Perry, M.R., Ward, S., Brett, S.J., Castello-Cortes, A., Brunner, M.D. et al. (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018-1028.[Abstract/Free Full Text]
• Tsunoda, I., Terry, E.J., Marble, B.J., Lazarides, E., Woods, C. and Fujinami, R.S. (2007) Modulation of experimental autoimmune encephalomyelitis by VLA-2 blockade. Brain Pathol 17: 45-55.[CrossRef][Medline] [Order article via Infotrieve]
• Tubridy, N., Behan, P.O., Capildeo, R., Chaudhuri, A., Forbes, R., Hawkins, C.P. et al. (1999) The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 53: 466-472.[Abstract/Free Full Text]
• van Oosten, B.W., Barkhof, F., Truyen, L., Boringa, J.B., Bertelsmann, F.W., von Blomberg, B.M. et al. (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated
• with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47: 1531-1534.
• Van Assche, G., Van Ransohoff, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M. et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362-368.[Abstract/Free Full Text]
• von Andrian, U.H. and Engelhardt, B. (2003) Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 348: 68-72.[Free Full Text]
• Voso, M.T., Pantel, G., Rutella, S., Weis, M., D'Alo, F., Urbano, R. et al. (2002) Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica 87: 918-925.[Abstract/Free Full Text]
• Watanabe, M., Amino, N., Hochito, K., Watanabe, K., Kuma, K. and Iwatani, Y. (1997) Opposite changes in serum soluble CD8 in patients at the active stages of Graves' and Hashimoto's diseases. Thyroid 7: 743-747.[Medline] [Order article via Infotrieve]
• Webster, A.C., Playford, E.G., Higgins, G., Chapman, J.R. and Craig, J. (2004) Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst RevCD003897.
• Wing, M.G., Moreau, T., Greenwood, J., Smith, R.M., Hale, G., Isaacs, J. et al. (1996) Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 98: 2819-2826.[Medline] [Order article via Infotrieve]
• Yanaba, K., Hamaguchi, Y., Venturi, G.M., Steeber, D.A., St Clair, E.W. and Tedder, T.F. (2007) B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol 179: 1369-1380.[Abstract/Free Full Text]
• Yousry, T.A., Major, E.O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J. et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924-933.[Abstract/Free Full Text]
• Zohren, F., Toutzaris, D., Klarner, V., Hartung, H.P., Kieseier, B. and Haas, R. (2008) The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 111: 3893-3895.[Abstract/Free Full Text]

Therapeutic Advances in Neurological Disorders, Vol. 1, No. 1, 33-42 (2008)
DOI: 10.1177/1756285608093945


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Linker, R. A. Articles by Kieseier, B. C. Search for Related Content Social Bookmarking                         What's this?